Class | Name/Company | Approval Dates and Comments |
Photodynamic Therapy |
Draxis Health/DUSA | TPP – Canada issued marketing approval to Draxis Health in June |
Monoclonal |
Schering Canada | TPP – Canada approved this monoclonal antibody for marketing in |
Antifungal |
Bertek Pharmaceuticals | The US FDA approved a new indication in June 2001, for this antifungal |
Antifungal |
| The US FDA approved this antifungal/corticosteroid cream in May |
Drug News | |
Drug Warning | The US FDA issued a warning to consumers in June 2001, to discontinue use of 13 Chinese herbal products |
Drug Warning | The US FDA issued a drug warning in June 2001, stating that myelosuppression, including anemia, pancyptopenia
|
Antiacne Agent | The US FDA granted six additional months of marketing exclusivity to Accutane® (Isotretinoin, Hoffmann |
Drug Interaction | In an article published in Clinical Pharmacology and Therapeutics*, Morii, et al, reported that when *Clin Pharmacol Ther 68(6):613-6 (2000). |
Oncologic Agent Re: Maxamine | The University of Pittsburgh Cancer Institute has reported that the immunomodulating agent Maxamine (histamine dihydrochloride), used in combination with interleukin-2 (IL-2), improved survival for stage IV malignant melanoma patients when compared to those treated with IL-2 alone. Preliminary results also indicated that treatment with Maxamine and IL-2 was safe and well tolerated and had substantially less toxicity than the high-dose regimens of IL-2. |
Urticaria Re: Allegra | In June 2000 Aventis Pharmaceuticals announced that Allegra (fexofenadine HCl) 30mg tablets are now available by prescription for the relief of seasonal allergic rhinitis and chronic idiopathic urticaria in children aged 6-11 years. The US FDA approved Allegra for this additional indication in February 2000. |